tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Shanghai Henlius Biotech’s HLX14 Receives Positive EMA Opinion

Story Highlights
Shanghai Henlius Biotech’s HLX14 Receives Positive EMA Opinion

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an update.

Shanghai Henlius Biotech, Inc. announced that its biosimilar drug HLX14, a recombinant anti-RANKL human monoclonal antibody injection, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation for approval is a significant step towards gaining centralized marketing authorization across the EU and EEA countries. The positive opinion is based on data demonstrating analytical similarity and clinical efficacy compared to the reference drug, denosumab. This development positions Henlius as a competitive player in the global biosimilar market, with potential implications for stakeholders as the drug progresses towards final approval.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development of biosimilar drugs. The company specializes in creating treatments for various conditions, including osteoporosis and bone-related diseases, with a market focus on global commercialization except for certain regions in China.

Average Trading Volume: 1,276,778

Technical Sentiment Signal: Buy

Current Market Cap: HK$33.83B

For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1